16 January 2017 - A small Australian-listed pharmaceutical company is raising eyebrows in Washington DC and with the US media after it was linked to powerful players in Donald Trump’s inner circle, including the US president-elect’s pick for Health Secretary, Tom Price.

Innate Immunotherapeutics’ chief executive Simon Wilkinson and chairman Michael Quinn said they had never heard of many of the prominent US investors who have bought stock in the company.

They told The New York Times they first learned about Price’s involvement when The Wall Street Journal wrote about it last month.

Read The Australian article